OPERATING AND REPORTABLE SEGMENTS

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

The Company's operating and reportable segments, “Infusion Services," "Home Health Services” and “PBM Services,” reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of self-injectable therapies.

The Home Health Services operating and reportable segment provides services including the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home.

The PBM Services operating and reportable segment consists of integrated pharmacy benefit management ("PBM") services, which primarily consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at any of the Company's participating network pharmacies receive prescription medications at a discounted price compared to the retail price.

The Company's chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition, integration, and transitional expenses; restructuring expense; and other expenses related to the Company's strategic assessment. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company's summary of significant accounting policies.

Segment Reporting Information

(in thousands)

	Three Months Ended March 31,
	2013			2012
Results of Operations:
Revenue:
Infusion Services - product revenue	$	150,024		$	106,803
Infusion Services - service revenue	4,353			2,250
Total Infusion Services revenue	154,377			109,053
Home Health Services - service revenue	17,942			16,711
PBM Services - service revenue	26,752			29,869
Total revenue	$	199,071		$	155,633
Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	12,315		$	7,783
Home Health Services	883			1,080
PBM Services	6,199			6,098
Total Segment Adjusted EBITDA	19,397			14,961
Corporate overhead	(7,916		)	(6,582		)
Interest expense, net	(6,478		)	(6,569		)
Income tax benefit	(58		)	502
Depreciation	(2,459		)	(1,931		)
Amortization of intangibles	(2,082		)	(879		)
Stock-based compensation expense	(1,973		)	(966		)
Acquisition and integration expenses	(4,623		)	(172		)
Restructuring and other expenses	(1,278		)	(387		)
Loss from continuing operations, net of income taxes	$	(7,470	)	$	(2,023	)
Supplemental Operating Data
	March 31, 2013			December 31,  2012
Total Assets:
Infusion Services	$	523,857		$	438,623
Home Health Services	63,280			62,403
PBM Services	30,909			36,354
Corporate unallocated, including cash and cash equivalents	45,189			95,813
Assets associated with discontinued operations, not sold	2,479			9,183
Total	$	665,714		$	642,376